ROKIO Canadian Trademark Information
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, insomnia, and smoking habits or addictions; neurological disorders, namely brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease, cerebral palsy; genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; musculoskeletal disorders, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, fractures, sprains, cartilage injuries; inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; the respiratory system; infectious diseases, namely respiratory infections, eye infections; immunological disorders, namely autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS); viral disorders, namely herpes, hepatitis, Acquired Immune ...
Perfect for these industries
Words that describe this mark
pharmaceutical preparations treatment central nervous diseases disorders central nervous infections brain diseases central nervous movement disorders ocular motility disorders spinal cord diseases encephalitis epilepsy alzheimers cerebral palsy
Abandonment Notice!
On Wednesday, April 29, 2009,
status on the ROKIO
trademark changed to Interruption of proceeding.
Apply Now for this name starting at $449!
CAUTION: Although Canada registration for this particular filing is inactive,
the mark may still enjoy common law rights, or may have been applied for again in a separate application.
Further research may be warranted to determine where this mark is truly abandoned in commerce.
On Tuesday, April 8, 2003, a canadian trademark registration was filed for
ROKIO by Agouron Pharmaceuticals, Inc. *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
1173976.
The current status of this trademark filing is Interruption of proceeding.
The correspondent listed for
ROKIO is
GOWLING WLG (CANADA) LLP of *********, **********, ***** ****
The ROKIO
trademark is filed in the description of
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, insomnia, and smoking habits or addictions; neurological disorders, namely brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease, cerebral palsy; genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; musculoskeletal disorders, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, fractures, sprains, cartilage injuries; inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; the respiratory system; infectious diseases, namely respiratory infections, eye infections; immunological disorders, namely autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS); viral disorders, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); fungal disorders, namely, antifungals, pharmaceutical preparations, namely cholesterol preparations, namely preparations to lower cholesterol; pharmaceutical preparations for use in gynecology.
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information